FY2018 Earnings Forecast for Opiant Pharmaceuticals Inc Issued By Zacks Investment Research (OPNT)

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) – Equities research analysts at Zacks Investment Research dropped their FY2018 earnings estimates for Opiant Pharmaceuticals in a report issued on Tuesday. Zacks Investment Research analyst D. Bautz now anticipates that the technology company will post earnings of ($6.63) per share for the year, down from their previous estimate of ($5.12).

Other analysts also recently issued research reports about the stock. TheStreet raised shares of Opiant Pharmaceuticals from a “c+” rating to a “b” rating in a report on Monday, October 16th. ValuEngine downgraded shares of Opiant Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, October 2nd.

Shares of Opiant Pharmaceuticals (NASDAQ OPNT) traded up $5.54 during midday trading on Thursday, hitting $23.70. 394,600 shares of the stock were exchanged, compared to its average volume of 39,421. The stock has a market cap of $37.55, a P/E ratio of 43.24 and a beta of -2.33. Opiant Pharmaceuticals has a 12-month low of $5.00 and a 12-month high of $51.90.

Opiant Pharmaceuticals (NASDAQ:OPNT) last released its quarterly earnings data on Monday, December 4th. The technology company reported ($2.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.19) by ($1.58). The firm had revenue of $0.02 million for the quarter. Opiant Pharmaceuticals had a net margin of 8.93% and a return on equity of 42.44%.

In other news, major shareholder Geoffrey Wolf sold 34,938 shares of the firm’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $22.67, for a total transaction of $792,044.46. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 63.82% of the company’s stock.

WARNING: “FY2018 Earnings Forecast for Opiant Pharmaceuticals Inc Issued By Zacks Investment Research (OPNT)” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/12/21/fy2018-earnings-forecast-for-opiant-pharmaceuticals-inc-issued-by-zacks-investment-research-opnt.html.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).

Earnings History and Estimates for Opiant Pharmaceuticals (NASDAQ:OPNT)

What are top analysts saying about Opiant Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Opiant Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit